Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q1 2025 Earnings Presentation
6 slides from Avita Medical's earnings presentation, May 8, 2025
Slide 1: Q1 2025 Earnings Presentation
Q1 2025 Earnings Presentation May 8, 2025
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and un
Slide 3: From a $455M U.S. Burn Market to a $3.5B+ Acute Wound Care Opportunity
FROM A $455M U.S. BURN MARKET to a $3.5B+ Acute Wound Care Opportunity 2019 2023 2025 Long-Term BURN-ONLY, BURN & TRAUMA, BURN & TRAUMA, BURN & TRAUMA, SINGLE-PRODUCT SINGLE-PRODUCT MULTI-PROD UCT MULTI-PROD UCT $455M $1.3B $3.5B >$3.5B TAM (U.S.) TAM (U.S.) TAM (U.S.) TAM Scaling TAM through 1 Port
Slide 4: Revenue Per Case Potential Across Our Acute Wound Portfolio
COMPATIBLE SOLUTIONS Revenue Per Case Potential Across Our Acute Wound Portfolio Our TAM expands from Two-Stage Procedure: Full-Thickness Wound $450 million to $1.5 billion in burn market alone TBSA: 10% to 20% Potential Revenue Per Case3 PermeaDerm $2,000 – $4,000 Dressing RECELL1 $6,500 – $13,000
Slide 5: Sustained Revenue Growth and Strong CAGR
HISTORICAL ANNUAL REVENUE Sustained Revenue Growth and Strong CAGR Annual Global Revenue +47% CAGR‡ $120 61%† $100 Commercial Revenue $80 ($ in millions) 28% $60 47% $40 17% 32% 120% $20 $10 $22 $29 $34 $50 $64 $100-$106 $0 2019* 2020* 2021* 2022 2023 2024 2025F† ‡ Estimated compound annual growth r
Slide 6: Slide 6